Member Info for Hurst10

More to come, one would suspect.

Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology.

Watch the price in size.
Nothing around
Happy trading Wednesday, pre 10AM

Just look up post news flow from their visit / presence in previous years!!
Anyway, ultra important and everybody is there.
Much will happen beforehand !

Watch it
Pre ASCO

Go private

Just the beginning
Big boys moving in
Soon there will be no stock around

145-50 I’m NY size

Size buyer back in town

Novartis buying radioligand therapy
After putting in a $50 million cash bid for the Clovis program, Novartis is now coming back to 3BP for a broader deal that encompasses worldwide rights to develop and commercialize all therapeutic and imaging applications of 3BP’s FAP-targeting peptide technology.

Novartis guiding higher, helped by and looking to invest in “new medicines “!!!

With last week’s M&A volume and prices paid, today’s RNS and ASCO coming up, current price, makes it bargain of the year.
Watch out for 10AM, we will move much higher. They want stock and in size.
MM front running this happening.
Who can blame them!
Early coffee being lined up on the Street.

Another scoop for Point Biopharma!
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Expect steady news flow up to the Oncology event of the year ASCO,June 2-Jun 6!!
M&A will accelerate, Therapeutic valuations will fly and NY investors will be watching and buying!

Post ACCR, strong upswing in M&A in Biotech.
$12bill just in last week!
Read across valuation !!

Worth remembering the noises so far from the AVA3396, suggests this drug could possible overtake AVA6000 in the inside lane and one could have the FDA helping it along.
To put a value of the AVA family would make current share price look even more undervalued.
Interesting FY results presentation coming up.
One trading day left

Coming into opening bells, volume is picking up and being only 2 hours and one day away from FY numbers and further update+investor presentation and Q&A, you cannot blame size buyers wanting more!

Range of kits for the detection of COVID-19 by PCR.Launch Diagnostics and its partner Anatolia Geneworks have been at the forefront of the SARS-CoV-2 testing since the beginning of the pandemic. The COVID-19 PCR range is extensively used worldwide and in the NHS, public and private sectors in UK and in France. All the products are on the CTDA list of approved products with the MHRA.Anatolia launched their first CE marked SARS-CoV-2 PCR kit in February 2020, since then they have expanded the range to fit the ever changing clinical need as it develops.Key products in the COVID-19 PCR range are:Bosphore Novel Coronavirus (2019-nCoV) Detection Kit v4Bosphore SARS-CoV-2/Flu/RSV Panel KitBosphore SARS-CoV-2/Respiratory Pathogens Panel Kit Launch Diagnostics is a licensed reseller and distributor of Anatolia Geneworks SARS-CoV-2 PCR solutionLaunch Diagnostics, part of the Avacta group, provides pathology solutions encompassing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, Belgium, Luxemburg, France through Launch Diagnostics SAS and to the Republic of Ireland through ACCUSAY Diagnostics.Offering a large portfolio of diagnostic kits, laboratory instrumentation and services, our product range has expanded over the years to include a comprehensive range of EIA, single test devices, serology products, molecular assays and instrumentation.

Los Angeles County has identified its first cases of an emerging Omicron coronavirus subvariant dubbed Arcturus, a strain global health authorities are watching closely as it has been linked to an upswing in cases in India.

Watch QDEL- QuidelOrtho Corporation

First person dies with new Covid variant as cases rise globally.
New Arcturus Covid variant has unique new symptom, research suggests.
The strain has been found in a total of 29 countries.